Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Purpose</h3><p>To develop and validate a deep learning (DL)‐based radiomics model to predict the response to chemotherapy in colorectal liver metastases (CRLM).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>In this retrospective study, we enrolled 192 patients diagnosed with CRLM who received first‐line chemotherapy and were followed by response assessment. Tumor response was identified according to the Response Evaluation Criteria in Solid Tumors (RECIST). Contrast‐enhanced multidetector computed tomography (MDCT) images were fed as inputs of the ResNet10‐based DL radiomics model, and the possibility of response was predicted as the output. The final combined DL radiomics model was constructed by integrating the response related clinical factors and the developed DL radiomics signature. A time‐independent validation cohort (n=48) was extracted from the 192 patients to evaluate the DL model with area under the receiver operating characteristic curve (AUC), specificity, and sensitivity. Meanwhile, a traditional radiomics model was constructed using least absolute shrinkage and selection operator (lasso) as comparisons with the DL‐based model.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>According to RECIST criteria, 131 patients were identified as responders with complete response, partial response and stable disease, while 61 patients were non‐responders with progression disease. The selected predictive clinical factor turned out to be the carcinoembryonic antigen (CEA) level with AUC of 0.489 (95% confidence interval [CI], 0.380‐0.599) and 0.558 (95% CI, 0.374‐0.741) in the training and validation cohorts, respectively. The DL‐based model provided better performance than the traditional classifier‐based radiomics model with significantly higher AUC (training: 0.903 [95% CI, 0.851‐0.955] vs.0.745 [95% CI, 0.659‐0.831]; validation: 0.820 [95% CI, 0.681‐0.959] vs. 0.598 [95% CI, 0.422‐0.774]). The combination of DL‐based model with the CEA level provided slightly increased performance with AUC of 0.935 [95% CI, 0.897‐0.973] in the training cohort and 0.830 [95% CI, 0.688‐0.973] in the validation cohort.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>The developed DL‐based radiomics model could improve the efficiency to predict the response to chemotherapy in CRLM, which may assist in subsequent personalized treatment decision‐making in CRLM management.</p></section>

Treatment response prediction of neoadjuvant chemotherapy for rectal cancer by deep learning of colonoscopy images

Machine learning for prediction of chemoradiation therapy response in rectal cancer using pre-treatment and mid-radiation multi-parametric MRI

Predicting response to neoadjuvant chemotherapy for colorectal liver metastasis using deep learning on prechemotherapy cross‐sectional imaging

Deep learning model for predicting treatment response for patients with rectal cancer using 3D medical imaging.

Deep learning model based on endoscopic images predicting treatment response in locally advanced rectal cancer undergo neoadjuvant chemoradiotherapy: a multicenter study

Deep Learning for Prediction of Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer: A Retrospective Multi-Cohort Pathomics Study

Predicting Rectal Cancer Response to Neoadjuvant Chemoradiotherapy Using Deep Learning of Diffusion Kurtosis MRI

A Longitudinal MRI-Based Artificial Intelligence System to Predict Pathological Complete Response after Neoadjuvant Therapy in Rectal Cancer: A Multicenter Validation Study.

A Deep Learning Model to Predict the Response to Neoadjuvant Chemoradiotherapy by the Pretreatment Apparent Diffusion Coefficient Images of Locally Advanced Rectal Cancer

Computed tomography-based deep-learning prediction of neoadjuvant chemoradiotherapy treatment response in esophageal squamous cell carcinoma

Evaluation of Neoadjuvant Chemoradiotherapy Response in Rectal Cancer Using MR Images and Deep Learning Neural Networks

Endoscopy-Based Deep Convolutional Neural Network Predicts Response to Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Deep Learning Model for Predicting the Pathological Complete Response to Neoadjuvant Chemoradiotherapy of Locally Advanced Rectal Cancer

Deep learning of endoscopic features for the assessment of neoadjuvant therapy response in locally advanced rectal cancer

Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer

Predicting treatment response for the safe non-operative management of patients with rectal cancer using an MRI-based deep-learning model.

Deep learning‐based radiomics predicts response to chemotherapy in colorectal liver metastases

Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer

Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study

Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study

Deep learning-based prediction of response to HER2-targeted neoadjuvant chemotherapy from pre-treatment dynamic breast MRI: A multi-institutional validation study